Articles by Fred D. Lublin, MD
Classification and Diagnosis of SPMS
ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD Fred D. Lublin, MD, leads a discussion about the different classifications of secondary progressive multiple sclerosis, including the relationship between disease activity and progression of disease.
Diagnosing SPMS
ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD An overview of the criteria used to diagnose relapsing-remitting multiple sclerosis when it converts to secondary progressive multiple sclerosis.
Clinical Subtypes of MS
ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD A panel of experts led by Bruce Cree, MD, highlight the clinical subtypes of multiple sclerosis including presentation and prevalence.
The Future of Treating Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Decision-Making Process for Treating Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Switching Therapies in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Role of Ozanimod in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Role of Diroximel Fumarate in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Role of Ocrelizumab in Europe for Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Ocrelizumab for the Treatment of Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Role of Siponimod in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Treating With Cladribine in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Clinical Trials for Cladribine in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
The Use of Glatiramer Acetate in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
The Use of Interferon in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
First-Line Therapies for Relapsing Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Clinically Isolated Syndrome Versus Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
MOG-IgG in Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Differential Diagnosis of Multiple Sclerosis
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD 
Diagnosis of Multiple Sclerosis: The McDonald Criteria
BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD
